前列腺癌放疗中可植入直肠间隔物的系统综述
PURPOSE: This systematic review provides an overview of the available literature regarding the efficacy and safety of implantable rectal spacers (IRSs) in reducing rectal dose and gastrointestinal toxicity during prostate cancer radiation therapy.…
要点
- 水凝胶、透明质酸和直肠球囊间隔物已有随机对照试验数据,人胶原仅有单臂初步研究。
- 直肠与前列腺之间1厘米的间距足以保护直肠这一主要剂量限制器官。
核心结论
- 将IRS整合入临床实践有潜力改善前列腺癌患者的治疗格局,但其使用应基于对个体患者需求的审慎考量,以确定最可能获益的患者。
研究设计与样本
- 纳入研究聚焦不良事件、直肠剂量降低、胃肠道毒性或肠道生活质量,并评估IRS植入技术、安全性和间距。
主要发现
- 水凝胶、透明质酸和直肠球囊间隔物有随机对照试验数据,人胶原仅有单臂初步研究,近距离放疗中IRS的前瞻性临床研究有限。
- 直肠与前列腺之间1厘米的间距足以保护直肠这一主要剂量限制器官。
- 使用水凝胶间隔物时总体并发症率为0,96%,临床试验中未报告4至5级胃肠道毒性。
- 使用IRS与长期肠道生活质量改善相关。
关键数值与推荐
- 水凝胶间隔物总体并发症率为0,96%。
- 临床试验中未报告4至5级胃肠道毒性。
- 直肠与前列腺之间1厘米间距足以保护直肠。
临床怎么用
- IRS可整合入临床实践以改善前列腺癌患者的治疗,但需根据个体患者需求审慎选择最可能获益者,并非所有患者均能同等获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This systematic review provides an overview of the available literature regarding the efficacy and safety of implantable rectal spacers (IRSs) in reducing rectal dose and gastrointestinal toxicity during prostate cancer radiation therapy. METHODS AND MATERIALS: A comprehensive literature search was conducted in December 2024. Results included prospective research in humans and were limited to the English language. The 30 included studies, all published between 2007 and 2024, were randomized controlled trials or clinical trials that focused on adverse events, rectal dose reduction, gastrointestinal toxicity, or bowel quality of life. Next, IRS implantation technique, safety, and spacing distance were assessed. RESULTS: Randomized controlled trial data were available for hydrogel, hyaluronic acid, and rectal balloon implant spacers, whereas only one pilot study is available for human collagen. Prospective clinical research on IRS in brachytherapy is limited. One centimeter of spacing between the rectum and prostate sufficed to spare the rectum, the primary dose-limiting organ. Findings indicate a favorable safety profile, with an overall complication rate of 0,96% when using hydrogel spacers. There was no grade 4 to 5 gastrointestinal toxicity reported in clinical trials. The use of an IRS was associated with improved long-term bowel quality of life. CONCLUSIONS: The integration of IRS into clinical practice offers the potential to enhance the therapeutic landscape for patients with prostate cancer. However, its use should be guided by careful consideration of individual patient needs to determine those who benefit most from the IRS because not all patients may benefit equally.
引用
- Lippens J, Willems L, Boychak O, et al. Implantable Rectal Spacers in Prostate Cancer Radiation Therapy: A Systematic Review. Pract Radiat Oncol. 2025. PMID: 40246071. doi:10.1016/j.prro.2025.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。